Program
recombinant human thrombopoietin
Also written as “Recombinant human thrombopoietin”, “rhTPO” and “Recombinant human thrombopoietin for injection (rhTPO)”.
Its studies are mostly in Thrombocytopenia · Liver Cirrhosis, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| 3SBio | 30 open or running | phase 1since Dec 31, 2021 | Aug 15, 2018 | none ahead |
| MIBIO PTE. | 11 open or running | phase 3since Oct 28, 2026 | Oct 28, 2026 | Oct 31, 2028phase 3 · NCT07911800 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 15, 2018First study: early phase 1 study in Liver CirrhosisNew to 3SBio3SBio · NCT03673215 · 58 enrolled · China
- Dec 31, 2021Phase 1 study in Thrombocytopenia3SBio · NCT05193201 · 54 enrolled · China
- Oct 4, 2024Phase 1 study in Healthy Subjects3SBio · NCT06630494 · 22 enrolled · Australia
- Oct 28, 2026MIBIO PTE.’s first study: phase 3 study in ThrombocytopeniaNew to MIBIO PTE.MIBIO PTE. · NCT07911800 · 150 planned · Georgia
Ahead
- Oct 31, 2028Primary completion: phase 3 study in ThrombocytopeniaMIBIO PTE. · NCT07911800
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07911800Thrombocytopenia · Georgia | 3 | Recruiting | MIBIO PTE. | Oct 31, 2028 | 150 |
| NCT06630494Healthy Subjects · Australia | 1 | Completed | 3SBio | Nov 18, 2024 | 22 |
| NCT05193201Thrombocytopenia · China | 1 | UNKNOWN | 3SBio | Oct 16, 2022 | 54 |
| NCT03673215Liver Cirrhosis · China | Early 1 | UNKNOWN | 3SBio | Oct 8, 2020 | 58 |
How it is read
Names in the registry
- “Recombinant human thrombopoietin”, 4 entries
- “rhTPO”, 1 entry
- “Recombinant human thrombopoietin for injection (rhTPO)”, 1 entry
- “recombinant human thrombopoietin injection”, 1 entry
- “recombinant human thrombopoietin”, 1 entry
Conditions, from the studies’ own filings
- Thrombocytopenia, 2 studies
- Liver Cirrhosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.